Arrowhead Pharmaceuticals Inc (ARWR)
33.93
+1.91 (+5.96%)
USD |
NASDAQ |
Dec 02, 16:00
33.92
-0.01 (-0.03%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 3.597B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -51.31% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 14.79 |
| Price to Book Value | 9.025 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 80.58% |
News
Headline
Wire
Time (ET)
MT Newswires
11/30 07:44
MT Newswires
11/29 09:23
MT Newswires
11/29 09:23
MT Newswires
11/29 09:12
MT Newswires
11/29 07:45
Yahoo
11/28 16:30
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/02/2023* | 16:30 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 02/02/2023* | -- | Results | Q1 2023 | -- | -0.09 | -- | |
| 11/28/2022 | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 11/28/2022 | -- | Results | Q4 2022 | -0.81 | -0.54 | -48.84% | |
| 08/04/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/04/2022 | -- | Results | Q3 2022 | -0.68 | -0.51 | -33.74% | |
| 05/10/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/10/2022 | -- | Results | Q2 2022 | 0.41 | 0.18 | 124.2% |
*Estimated Date/Time
Earnings
Profile
Edit
| Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease. |
| URL | https://www.arrowheadpharma.com |
| Investor Relations URL | https://ir.arrowheadpharma.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Feb. 02, 2023 (est.) |
| Last Earnings Release | Nov. 28, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of December 02, 2022.
Fundamentals
| Revenue (TTM) | 243.23M |
| Total Expenses (TTM) | 421.74M |
| Net Income (TTM) | -176.06M |
| Total Assets (Quarterly) | 691.94M |
| Total Liabilities (Quarterly) | 273.60M |
| Shareholders Equity (Quarterly) | 398.52M |
| Cash from Operations (TTM) | -136.13M |
| Cash from Investing (TTM) | -5.417M |
| Cash from Financing (TTM) | 65.19M |
Ratings
Profile
Edit
| Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease. |
| URL | https://www.arrowheadpharma.com |
| Investor Relations URL | https://ir.arrowheadpharma.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Feb. 02, 2023 (est.) |
| Last Earnings Release | Nov. 28, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ARWR Tweets |